AstraZeneca Reports Phase 3 INAVO120 Results for Inavolisib in PIK3CA-Mutated Breast Cancer

AstraZeneca today announced results from the Phase 3 INAVO120 trial evaluating inavolisib plus palbociclib plus fulvestrant versus placebo plus palbociclib plus fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer who had relapsed on or after adjuvant endocrine therapy. The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival. The median PFS was 15.0 months for inavolisib versus 7.3 months for placebo. Inavolisib is a selective PI3Kα inhibitor with a differentiated mechanism that degrades mutant PI3Kα.